Genitourinary Cancer Research

Genitourinary Cancer Research

Research into genitourinary and prostate cancer at Penn State Cancer Institute is conducted by the genitourinary cancer team. See current clinical trials and members of that team here.

Clinical Trials

Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Locally Advanced Urothelial Cancer with Selected FGFR Gene Alterations
Patient perceptions regarding routine oncologic follow-up for urologic malignancies.
Targeting PIM1 and CDK4/6 Kinases in Renal Cell Carcinoma (PICKRCC): A Phase Ib study of Abemaciclib in Combination with Sunitinib in metastatic RCC
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase III Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma
A Phase 2b, Single- Arm, Multicenter Trial to Evaluate the Effficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle- Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrance
Use of a Multiplexed Molecular Biomarker Test Cxbladder, in Real World Decision Making to Provide Clinical Utility Using a Randomized Design
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
NRG-GU005 Phase III IGRT and SBRT VS IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer
Computer-Aided Diagnosis of Cancer in Urinary Tract on Multi-Detector Row CT Urography
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE)
Follow up for patients on Phase lb Clinical Trial of Eribulin Mesylate and the PD-Ll Monoclonal Antibody, Avelumab, in Cisplatin Ineligible or Platinum Resistant Metastatic Urothelial Cell Cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Enhancing Patient Resilience During Multimodal Therapy for Bladder Cancer
Creation of a Clinical and Pathologic Tissue Microarray Registry for Radical Cystectomy Specimens
Complications in Patients Undergoing Radical Cystectomy for Bladder Cancer
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome
Research into genitourinary and prostate cancer at Penn State Cancer Institute is conducted by the genitourinary cancer team. See current clinical trials and members of that team here.
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Locally Advanced Urothelial Cancer with Selected FGFR Gene Alterations
Patient perceptions regarding routine oncologic follow-up for urologic malignancies.
Targeting PIM1 and CDK4/6 Kinases in Renal Cell Carcinoma (PICKRCC): A Phase Ib study of Abemaciclib in Combination with Sunitinib in metastatic RCC
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase III Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma
A Phase 2b, Single- Arm, Multicenter Trial to Evaluate the Effficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle- Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrance
Use of a Multiplexed Molecular Biomarker Test Cxbladder, in Real World Decision Making to Provide Clinical Utility Using a Randomized Design
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
NRG-GU005 Phase III IGRT and SBRT VS IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer
Computer-Aided Diagnosis of Cancer in Urinary Tract on Multi-Detector Row CT Urography
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE)
Follow up for patients on Phase lb Clinical Trial of Eribulin Mesylate and the PD-Ll Monoclonal Antibody, Avelumab, in Cisplatin Ineligible or Platinum Resistant Metastatic Urothelial Cell Cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Enhancing Patient Resilience During Multimodal Therapy for Bladder Cancer
Creation of a Clinical and Pathologic Tissue Microarray Registry for Radical Cystectomy Specimens
Complications in Patients Undergoing Radical Cystectomy for Bladder Cancer
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)